In a lung cancer H460 xenograft model, the simultaneous inhibition of GPX4 and FSP1 was necessary to suppress tumor growth, suggesting that therapies targeting GPX4 alone might fail due to the compensatory activation of FSP1 [11]. The gene discussed is AIFM2; the disease is lung cancer.